Journal
EBIOMEDICINE
Volume 59, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ebiom.2020.102944
Keywords
alpha-Synuclein; Antisense oligonucleotide; Axonal neurodegeneration; Dopamine neurotransmission; Mouse and monkey models; Parkinson's disease
Funding
- Ministry of Economy and Competitiveness (MINECO) [SAF2016-75797-R, RTC-2014-2812-1, RTC-2015-3309-1]
- European Regional Development Fund (ERDF), UE [SAF2016-75797-R, RTC-2014-2812-1, RTC-2015-3309-1]
- Therapeutic Pipeline Program Spring 2014 Program, The Michael J. Fox Foundation [9238]
- Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM)
- Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED)
Ask authors/readers for more resources
Background: Progressive neuronal death in monoaminergic nuclei and widespread accumulation of alpha-synuclein are neuropathological hallmarks of Parkinson's disease (PD). Given that alpha-synuclein may be an early mediator of the pathological cascade that ultimately leads to neurodegeneration, decreased alpha-synuclein synthesis will abate neurotoxicity if delivered to the key affected neurons. Methods: We used a non-viral gene therapy based on a new indatraline-conjugated antisense oligonucleotide (IND-ASO) to disrupt the alpha-synuclein mRNA transcription selectively in monoamine neurons of a PD-like mouse model and elderly nonhuman primates. Molecular, cell biology, histological, neurochemical and behavioral assays were performed. Findings: Intracerebroventricular and intranasal IND-ASO administration for four weeks in a mouse model with AAV-mediated wild-type human alpha-synuclein overexpression in dopamine neurons prevented the synthesis and accumulation of alpha-synuclein in the connected brain regions, improving dopamine neurotransmission. Likewise, the four-week IND-ASO treatment led to decreased levels of endogenous alpha-synuclein protein in the midbrain monoamine nuclei of nonhuman primates, which are affected early in PD. Conclusions:: The inhibition of alpha-synuclein production in dopamine neurons and its accumulation in cortical/ striatal projection areas may alleviate the early deficits of dopamine function, showing the high translational value of antisense oligonucleotides as a disease modifying therapy for PD and related synucleinopathies. (C) 2020 The Authors. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available